Want to see TSE:MOOD full AI Analyst Report?
Top Page
Doseology Sciences
(MOOD)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.21
▲(8.42% Upside)
Action:Reiterated
Date:07/24/26
The score is weighed down primarily by weak financial performance (small/declining revenue, ongoing losses, and negative cash flow) and a bearish technical profile (below key moving averages with negative MACD). Valuation provides little support due to negative earnings and no dividend, while the debt-free balance sheet is a partial stabilizer.
Positive Factors
Debt-free balance sheet
A near-zero debt position and equity cushion materially reduce leverage risk and give the company more financing flexibility over the medium term. This durable strength lowers default risk and supports strategic options (M&A, licensing, or capital raises) while losses persist.
Negative Factors
Persistent operating losses
Large ongoing operating deficits relative to revenue show the business has not scaled to cover fixed costs. Persistent losses will continue to erode equity, limit reinvestment capacity, and force reliance on external capital unless meaningful margin improvements are achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A near-zero debt position and equity cushion materially reduce leverage risk and give the company more financing flexibility over the medium term. This durable strength lowers default risk and supports strategic options (M&A, licensing, or capital raises) while losses persist.
Read all positive factors
Doseology Sciences (MOOD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.48M
Dividend YieldN/A
Average Volume (3M)1.39K
Price to Earnings (P/E)―
Beta (1Y)-2.42
Revenue Growth73.76%
EPS Growth-108.30%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.08
Shares Outstanding8,011,621
10 Day Avg. Volume2,500
30 Day Avg. Volume1,390
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)3.46
Price to Sales (P/S)113.73
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Doseology Sciences Business Overview & Revenue Model
Company Description
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, ...
How the Company Makes Money
null...
Doseology Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.56K | 98.52K | 43.09K | 16.05K | 0.00 |
| Gross Profit | 18.89K | 72.09K | 41.29K | -148.38K | -92.83K |
| EBITDA | -471.61K | -319.48K | -1.78M | -1.72M | -1.47M |
| Net Income | -447.79K | -339.85K | -1.78M | -1.94M | -1.63M |
Balance Sheet | |||||
| Total Assets | 1.49M | 1.10M | 1.40M | 3.87M | 5.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.43M | 1.06M | 1.30M | 1.87M | 3.73M |
| Total Debt | 0.00 | 0.00 | 50.27K | 746.10K | 687.54K |
| Total Liabilities | 94.11K | 82.49K | 99.19K | 871.51K | 3.41M |
| Stockholders Equity | 1.40M | 1.02M | 1.30M | 3.00M | 2.58M |
Cash Flow | |||||
| Free Cash Flow | -342.24K | -235.12K | -481.05K | -1.72M | -2.54M |
| Operating Cash Flow | -342.24K | -235.12K | -481.05K | -1.71M | -2.37M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -7.88K | -26.05K |
| Financing Cash Flow | 711.68K | -6.14K | -91.88K | -140.08K | 5.79M |
Doseology Sciences Technical Analysis
Negative
0.19
Price Trends
0.18
Positive
0.30
Negative
0.49
Negative
Market Momentum
<0.01
Negative
48.18
Neutral
87.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.49, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 87.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MOOD.
Doseology Sciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:MOOD
Doseology Sciences
0.19
-0.32
-63.00%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.12
-0.06
-33.33%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.25
-3.76
-93.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.